14 Sep '22
Portage Biotech Provides Research and Development Update
--The Company Highlights its Clinical Strategy for its Adenosine and iNKT Platforms-- --Clinical Development Goals are Focused on Producing Phase 1b/Phase 2 Efficacy Readouts in Multiple Tumor Types Over the Next two Years-- WESTPORT, Conn. , Sept. 14, 2022 (GLOBE NEWSWIRE) -- Portage Biotech
08 Sep '22
Portage Biotech to Present at Upcoming Investor Conferences
WESTPORT, Conn. , Sept. 08, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced that the Company’s management team will be presenting at the following upcoming
29 Aug '22
Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022
--Robust Pipeline Now Includes Five Clinical-Stage Small Molecule Immuno-Oncology Assets, Including Invariant Natural Killer T Cell (iNKT) Agonists and Adenosine Antagonists-- ---Cash Runway for New and Current Programs Potentially Extended into 2024-- WESTPORT, Conn. , Aug.
18 Aug '22
Portage Biotech Announces Leadership Updates
CEO Dr. Ian Walters to take on additional responsibility as Chairman of the Board Justin Fairchild , MPH, an expert in clinical immunotherapy, appointed Vice President of Development WESTPORT, Conn. , Aug. 18, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc.
01 Aug '22
Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022
--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now Includes Four Fully Owned, Clinical-Stage Assets-- --Cash Runway for New and Current Programs Potentially Extended into 2024-- WESTPORT, Conn. , Aug.
Displaying 1 - 10 of 16